At the cellular and molecular levels, the protective effects were attributed to the role of MYSM1 in the cMYC-dependent induction of the genes encoding ribosomal proteins in the tumor cells (Rps/Rpl genes), with MYSM1-loss resulting in reduced Rps/Rpl transcript levels, reduced cellular protein synthesis rates, and the activation of p53 tumour suppressor40. This evidence concerns the gene MYSM1 and neoplasm.